Sanofi-Aventis Research and Development (SARD)

Sanofi-Aventis Research and Development (SARD)

Name of leader and affiliation
Sylvie Sordello, sanofi-aventis France for scientific input, Annabelle Milla, sanofi-aventis, France for project management.

As a research-based company, with global offices based in Paris (France), SARD TSU Infectious diseases is a new division of SARD, focused on the development of treatments of infectious diseases. SARD is a research oriented company that has developed a wide network of international academic collaborations in the field of neglected diseases and multi-drug resistant diseases. SARD has a strong expertise in antibiotics discovery and development.



Sorry, no posts found for this author.

Consortium Partners

PreDiCT-TB brings together twenty-one leading European research partners in tuberculosis from both Industry and Academia

View More

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115337, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.

The communication contained within this site reflects the author’s view and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained therein.